Franz P. Rischard
Expertise in
3
conditions

Dr. Franz P. Rischard

Pulmonary Medicine
Banner - University Medical Group
2800 East Ajo Way, 
Tucson, AZ 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
3
conditions
Banner - University Medical Group
2800 East Ajo Way, 
Tucson, AZ 

Overview

I enjoy advancing medicine through academics and excellent patient care.

Dr. Rischard is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Cerebral Hypoxia, and Systemic Sclerosis (SSc).

Dr. Rischard is board certified in American Board Of Internal Medicine/Critical Care Medicine and American Board Of Internal Medicine/Pulmonary Disease. He is actively involved in clinical research, co-authoring 98 peer reviewed articles and participating in 11 clinical trials. Dr. Rischard is currently accepting new patients.

Specialties

Pulmonary Medicine

Licenses

Internal Medicine in AZ

Board Certifications

American Board Of Internal Medicine/Critical Care Medicine
American Board Of Internal Medicine/Pulmonary Disease

Fellowships

University of Arizona College of Medicine, Pulmonary Disease, 2006

Hospital Affiliations

Banner - University Medical Center Tucson Campus
Banner-University Medical Center South Campus
Banner - University Medical Center South
Banner - University Medical Center Tucson

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Banner - University Medical Group
2800 East Ajo Way, Tucson, AZ 85713
Other Locations
Banner-University Medical Center Tucson Campus
1625 North Campbell Avenue, Tucson, AZ 85719

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Enrollment Status: Terminated
Publish Date: July 06, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: June 16, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
Enrollment Status: Terminated
Publish Date: June 08, 2026
Intervention Type: Other, Drug
Study Drug: Sotatercept
Study Phase: Phase 3
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated Interstitial Lung DiseasE and Pulmonary Hypertension (PH): The CRuSADE PH Study
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated Interstitial Lung DiseasE and Pulmonary Hypertension (PH): The CRuSADE PH Study
Enrollment Status: Withdrawn
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drug: Opsumit
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Completed
Publish Date: April 19, 2023
Intervention Type: Drug, Other
Study Drug: Sotatercept
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

98 Total Publications

Endotypes of Vascular Health Predict Transplantation-Free Survival in Pulmonary Hypertension.
Endotypes of Vascular Health Predict Transplantation-Free Survival in Pulmonary Hypertension.
Journal: Journal of the American Heart Association
Published: July 17, 2026
Similar Doctors
Expertise in
8
conditions
Dr. Kenneth S. Knox
Pulmonary Medicine
Expertise in
8
conditions
Dr. Kenneth S. Knox
Pulmonary Medicine
Referral may be required

Banner-University Medical Center Tucson

1501 N Campbell Ave, 
Tucson, AZ 
 (4.4 miles away)
520-694-2353
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kenneth Knox is a Pulmonary Medicine provider practicing medicine in Tucson, Arizona. Dr. Knox is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Coccidioidomycosis, Sarcoidosis, Acute Interstitial Pneumonia, and Interstitial Lung Disease. Dr. Knox is currently accepting new patients.

Expertise in
12
conditions
Dr. Sunil Natrajan
Pulmonary Medicine
Expertise in
12
conditions
Dr. Sunil Natrajan
Pulmonary Medicine
Referral may be required
Before you request

Nuvoair Medical PC

1 S Church Ave Ste 1200, 
Tucson, AZ 
 (3.9 miles away)
833-688-6247
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sunil Natrajan is a Pulmonary Medicine provider practicing medicine in Tucson, Arizona. Dr. Natrajan is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Bronchiectasis, Cerebral Hypoxia, and Gastrostomy. Dr. Natrajan is board certified in American Board Of Internal Medicine. Dr. Natrajan is currently accepting new patients.

Expertise in
4
conditions
Dr. Michael B. Insel
Pulmonary Medicine
Expertise in
4
conditions
Dr. Michael B. Insel
Pulmonary Medicine
Referral may be required
Before you request

Banner - University Medicine North

3838 North Campbell Avenue, Building 2, 
Tucson, AZ 
 (4.9 miles away)
520-694-8888
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Insel is a Pulmonary Medicine provider practicing medicine in Tucson, Arizona. Dr. Insel is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Lung Metastases, and Pneumonia. Dr. Insel is board certified in American Board Of Internal Medicine, American Board Of Internal Medicine/Critical Care Medicine, and American Board Of Internal Medicine/Pulmonary Disease. Dr. Insel is currently accepting new patients.

Frequently Asked Questions about Dr. Franz P. Rischard

How do I make an appointment with Dr. Franz P. Rischard?

You can book an appointment with Dr. Franz P. Rischard by calling their office at 520-694-8888. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Franz P. Rischard a top-rated expert for Pulmonary Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Franz P. Rischard is classified as an Elite expert for Pulmonary Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Franz P. Rischard specialize in?

While Dr. Franz P. Rischard is a Pulmonary Medicine, they have specific expertise in Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, and Cerebral Hypoxia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pulmonary Medicine.

Does Dr. Franz P. Rischard participate in research or clinical trials?

Yes. Dr. Franz P. Rischard has published 98 articles and abstracts on conditions like Pulmonary Hypertension. You can view a list of Dr. Franz P. Rischard's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Franz P. Rischard accept my insurance?

Dr. Franz P. Rischard accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 520-694-8888 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rischard's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile